Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroprotective Agents | 2 | 2022 | 960 | 1.030 |
Why?
|
| Pruritus | 3 | 2024 | 380 | 0.800 |
Why?
|
| Pentylenetetrazole | 4 | 2022 | 72 | 0.790 |
Why?
|
| Smell | 1 | 2024 | 261 | 0.780 |
Why?
|
| Cues | 1 | 2024 | 884 | 0.640 |
Why?
|
| Bromhexine | 2 | 2024 | 2 | 0.460 |
Why?
|
| Kynurenine | 3 | 2023 | 142 | 0.460 |
Why?
|
| Receptors, Opioid | 3 | 2022 | 145 | 0.420 |
Why?
|
| Dapsone | 2 | 2022 | 56 | 0.400 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2022 | 282 | 0.380 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2023 | 1816 | 0.290 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2022 | 905 | 0.290 |
Why?
|
| Status Epilepticus | 2 | 2022 | 464 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2023 | 4362 | 0.260 |
Why?
|
| Pilocarpine | 2 | 2022 | 64 | 0.250 |
Why?
|
| Ambroxol | 1 | 2024 | 3 | 0.240 |
Why?
|
| Expectorants | 1 | 2024 | 22 | 0.240 |
Why?
|
| Olfactory Bulb | 1 | 2024 | 198 | 0.210 |
Why?
|
| Sumatriptan | 1 | 2022 | 66 | 0.200 |
Why?
|
| Leprosy | 1 | 2022 | 126 | 0.200 |
Why?
|
| Ondansetron | 1 | 2022 | 95 | 0.200 |
Why?
|
| Potassium Channel Blockers | 1 | 2022 | 162 | 0.200 |
Why?
|
| Glyburide | 1 | 2022 | 117 | 0.200 |
Why?
|
| Calcineurin | 1 | 2022 | 236 | 0.190 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2024 | 261 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2022 | 123 | 0.170 |
Why?
|
| Cholestasis | 1 | 2023 | 385 | 0.170 |
Why?
|
| Anticonvulsants | 4 | 2022 | 1923 | 0.170 |
Why?
|
| Colitis, Ulcerative | 2 | 2024 | 1930 | 0.170 |
Why?
|
| Stroke | 1 | 2022 | 9791 | 0.170 |
Why?
|
| Cyclosporine | 1 | 2022 | 780 | 0.170 |
Why?
|
| Naltrexone | 1 | 2022 | 319 | 0.170 |
Why?
|
| Losartan | 1 | 2021 | 263 | 0.170 |
Why?
|
| Potassium Channels | 1 | 2022 | 538 | 0.170 |
Why?
|
| NF-kappa B | 3 | 2023 | 2491 | 0.170 |
Why?
|
| Optic Nerve | 1 | 2022 | 572 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 429 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 2444 | 0.150 |
Why?
|
| Serotonin | 1 | 2022 | 1047 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 590 | 0.140 |
Why?
|
| Animals | 17 | 2024 | 169418 | 0.140 |
Why?
|
| Seizures | 4 | 2023 | 2996 | 0.140 |
Why?
|
| NG-Nitroarginine Methyl Ester | 3 | 2022 | 262 | 0.140 |
Why?
|
| Benzamides | 1 | 2022 | 1381 | 0.140 |
Why?
|
| Interpersonal Relations | 1 | 2024 | 1439 | 0.140 |
Why?
|
| Rats | 5 | 2022 | 23839 | 0.130 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 2003 | 0.130 |
Why?
|
| Behavior, Animal | 1 | 2024 | 1882 | 0.130 |
Why?
|
| Mice | 9 | 2024 | 82045 | 0.120 |
Why?
|
| Indoles | 1 | 2022 | 1834 | 0.120 |
Why?
|
| Disease Models, Animal | 6 | 2023 | 18388 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2023 | 1095 | 0.120 |
Why?
|
| Rats, Wistar | 3 | 2022 | 1891 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1664 | 0.110 |
Why?
|
| Colitis | 1 | 2022 | 1244 | 0.110 |
Why?
|
| Psoriasis | 1 | 2021 | 947 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2022 | 10784 | 0.110 |
Why?
|
| Nitric Oxide | 4 | 2022 | 2146 | 0.100 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2023 | 117 | 0.100 |
Why?
|
| N-Methylaspartate | 2 | 2022 | 231 | 0.090 |
Why?
|
| Pyridines | 1 | 2022 | 2888 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2022 | 3590 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2024 | 2891 | 0.080 |
Why?
|
| Lithium | 2 | 2022 | 600 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2022 | 2816 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 4984 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2024 | 23638 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2021 | 2293 | 0.070 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 3837 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3253 | 0.070 |
Why?
|
| Skin | 1 | 2021 | 4520 | 0.070 |
Why?
|
| Epilepsy | 1 | 2023 | 3324 | 0.070 |
Why?
|
| Cytokines | 4 | 2023 | 7449 | 0.070 |
Why?
|
| Melanoma | 1 | 2024 | 5740 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 22365 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2023 | 6986 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2024 | 2067 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2024 | 205 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2023 | 6879 | 0.050 |
Why?
|
| Antipruritics | 1 | 2023 | 31 | 0.050 |
Why?
|
| Inflammation | 4 | 2024 | 10865 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2023 | 3234 | 0.050 |
Why?
|
| Drug Inverse Agonism | 1 | 2022 | 11 | 0.050 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2022 | 65 | 0.050 |
Why?
|
| Receptors, Cannabinoid | 1 | 2022 | 43 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2023 | 257 | 0.050 |
Why?
|
| Rhizome | 1 | 2021 | 8 | 0.050 |
Why?
|
| Electroshock | 1 | 2022 | 120 | 0.050 |
Why?
|
| Convulsants | 1 | 2022 | 70 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2023 | 288 | 0.050 |
Why?
|
| Buspirone | 1 | 2022 | 80 | 0.050 |
Why?
|
| Dizocilpine Maleate | 1 | 2022 | 173 | 0.050 |
Why?
|
| Ointments | 1 | 2021 | 58 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 3734 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 348 | 0.050 |
Why?
|
| Tryptophan | 1 | 2023 | 483 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2021 | 153 | 0.050 |
Why?
|
| Allopurinol | 1 | 2022 | 198 | 0.040 |
Why?
|
| Male | 6 | 2024 | 364781 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2022 | 678 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2022 | 3145 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2024 | 1136 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 716 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2023 | 797 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 12242 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2022 | 412 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2022 | 586 | 0.040 |
Why?
|
| Arginine | 1 | 2022 | 923 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2021 | 499 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2022 | 679 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 1136 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11857 | 0.040 |
Why?
|
| Brain | 1 | 2024 | 27438 | 0.030 |
Why?
|
| Humans | 14 | 2024 | 768451 | 0.030 |
Why?
|
| Morphine | 1 | 2020 | 658 | 0.030 |
Why?
|
| Quality of Life | 3 | 2023 | 13497 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2021 | 923 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2022 | 2229 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2021 | 798 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2022 | 1965 | 0.030 |
Why?
|
| Antioxidants | 1 | 2022 | 1678 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2150 | 0.030 |
Why?
|
| Colon | 1 | 2022 | 1804 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 6241 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 1683 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2024 | 8332 | 0.030 |
Why?
|
| Aspirin | 1 | 2023 | 3139 | 0.020 |
Why?
|
| Intestines | 1 | 2021 | 1912 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2024 | 4948 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 17149 | 0.020 |
Why?
|
| Disease Progression | 1 | 2024 | 13655 | 0.020 |
Why?
|
| Sleep | 1 | 2023 | 4796 | 0.020 |
Why?
|
| Lung | 1 | 2024 | 10090 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 8051 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 11930 | 0.010 |
Why?
|
| Infant | 1 | 2024 | 36497 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2024 | 42623 | 0.010 |
Why?
|
| Female | 2 | 2022 | 396943 | 0.010 |
Why?
|
Concepts
(138)
Derived automatically from this person's publications.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_